查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1632577

全球轉甲狀腺素類澱粉沉積症治療市場：市場規模、佔有率和趨勢分析（按治療方法、類型、疾病、分銷管道、地區和細分，2025-2030 年）

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

轉甲狀腺素類澱粉沉積症治療市場的成長與趨勢：

根據 Grand View Research 的新報告，全球轉甲狀腺素類澱粉沉積症治療市場預計到 2030 年將達到 165.3 億美元。

預計 2025 年至 2030 年期間市場複合年成長率為 13.9%。轉甲狀腺素類澱粉沉積症治療市場主要受到支持性報銷計劃和不斷成長的非裔美國人口的推動。由於非裔美國更容易患 ATTR類澱粉沉積症，非裔美國人口的增加在整個時期內成為了該行業成長的催化劑。 Val122Ile 是導致全球 65 歲或以上人群患心肌病的最常見突變。此外，全球 3% 至 4% 的非裔美國存在 Val122Ile 突變。

預計，加強開發新診斷技術和多學科治療方法的研究活動將提高轉甲狀腺素類澱粉沉積症的存活率和改善預後。例如，2019年11月，類澱粉沉積症研究聯盟開發了一種特異性疾病的患者報告結果（PRO）工具，以從患者的觀點了解和衡量轉甲狀腺素類澱粉沉積症的影響。透過了解疾病的複雜性和患者的需求，這些工具的引入將促進對新目標特異性藥物的開發研究，從而擴大轉甲狀腺素類澱粉沉積症治療市場的機會。

主要企業採取的策略性舉措，例如提高對 ATTR 等目標疾病的認知以及現有治療方法的長期益處，預計將推動該行業的發展。例如，2019年，輝瑞與世界心臟聯盟合作發起了「心臟英雄」宣傳活動。透過此次宣傳活動，輝瑞公司向患者和醫生提供與 ATTR-CM 相關的教育資訊和資源。希望此類宣傳活動能促進 ATTR-CM 的早期診斷並提高長期治療率。

作為企業社會責任 (CSR) 活動的一部分，主要企業提供免費醫療服務的措施也有望推動市場成長。例如，輝瑞的病患援助計畫為符合資格的病患免費提供輝瑞藥物，包括 VYNDAMAX。被診斷患有類澱粉沉積症的人可以在 Vandalink 平台上註冊以享受此類計劃。希望該計畫能鼓勵醫生將該藥物作為轉甲狀腺素類澱粉沉積症患者的藥物治療。

轉甲狀腺素類澱粉沉積症治療市場：分析概述

  • 依照類型分類，由於疾病盛行率高且老齡人口不斷增加，到 2024 年，ATTR-CM 將佔據主要佔有率。預計 ATTR-PN 將在整個預測期內呈現最快的成長率。該領域的成長歸功於強大的管道。
  • 根據治療方法，由於全球範圍內對 ATTR-CM 治療的治療方法的核准和處方率不斷提高，標靶治療領域將在 2024 年佔據主導地位。
  • 根據疾病類型，遺傳性轉甲狀腺素類澱粉沉積症變性類疾病在 2024 年佔據了市場主導地位。這是由於藥物研發管道不斷擴大以及各製藥公司之間以藥物開發為目標的策略聯盟不斷擴大。
  • 按分銷管道分類，預計醫院藥房將在 2024 年佔據最大佔有率，因為大多數醫院都從事轉甲狀腺素類澱粉沉積症的診斷、研究和治療。
  • 2024 年，北美地區佔據最大佔有率，這得益於該地區新藥處方的增加、優惠的報銷政策以及較高的治療率。
  • 預計中東和非洲地區在整個預測期內將呈現最快的成長率。此細分市場的成長歸因於 ATTR類澱粉沉積症盛行率的增加。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 轉甲狀腺素類澱粉沉積症治療市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 轉甲狀腺素類澱粉沉積症治療市場：依治療方法進行的商業分析

  • 治療方法的市場佔有率（2024 年和 2030 年）
  • 治療方法儀表板
  • 市場規模預測及治療方法趨勢分析（2018-2030）
  • 標靶治療
  • 支持治療
  • 管道療法

第 5 章 轉甲狀腺素類澱粉沉積症治療市場：按類型進行的商業分析

  • 按類型分類的市場佔有率（2024 年和 2030 年）
  • 按類型分類的儀表板
  • 按類型分類的市場規模預測及趨勢分析（2018-2030）
  • ATTR神經病變(ATTR-PN)
  • ATTR心肌病(ATTR-CM)

6. 轉甲狀腺素類澱粉沉積症治療市場：依疾病進行的商業分析

  • 各疾病的市場佔有率（2024 年和 2030 年）
  • 疾病儀表板
  • 市場規模預測及疾病趨勢分析（2018-2030）
  • 遺傳性轉甲狀腺素類澱粉沉積症
  • 野生型類澱粉沉積症

7. 轉甲狀腺素類澱粉沉積症治療市場：按分銷管道進行的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2030 年）
  • 分銷通路儀表板
  • 按分銷管道分類的市場規模預測及趨勢分析（2018-2030 年）
  • 醫院藥房
  • 專業藥房
  • 零售藥局
  • 網路藥局

第 8 章 轉甲狀腺素類澱粉沉積症治療市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 按國家/地區分類（2018-2030 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類（2018-2030 年）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區分類（2018-2030 年）
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區分類（2018-2030 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 參與企業概況
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Pfizer Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals
    • AstraZeneca
    • Akcea Therapeutics
    • BridgeBio Inc.
    • Intellia Therapeutics, Inc.
    • SOM BIOTECH
    • Oncopeptides AB
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68039-977-9

Transthyretin Amyloidosis Treatment Market Growth & Trends:

The global transthyretin amyloidosis treatment market size is anticipated to reach USD 16.53 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 13.9% from 2025 to 2030. The transthyretin amyloidosis treatment market is mainly driven by the presence of supportive reimbursement programs and the growing African American population. The increasing African American population acted as a catalyst for the industry growth throughout the period owing to the high susceptibility to ATTR amyloidosis. The Val122Ile is the most prevalent mutation worldwide that leads to cardiomyopathy among the population specific to aged 65 years and above. Furthermore, this Val122Ile mutation is present in 3% to 4% of the African American population worldwide.

An increase in research activities for the development of novel diagnostic techniques and multidisciplinary therapeutic approaches is expected to lead to an increased survival rate and a more favorable prognosis of transthyretin amyloidosis. For instance, in November 2019, the Amyloidosis Research Consortium developed a disease-specific patient-reported outcome (PRO) tool to understand and measure the impact of transthyretin amyloidosis from the patient perspective. An introduction of such a tool will boost the research in developing a new target-specific drug by understanding disease complexity and patients' need, thereby widening the opportunity in the transthyretin amyloidosis treatment market.

Strategic initiatives undertaken by major players such as creating awareness regarding the target conditions such as ATTR and the long-term benefits of available therapies are expected to fuel industry growth. For instance, in 2019, Pfizer, Inc., in collaboration with the World Heart Federation, started the "Heart Hero" campaign. Under this campaign, Pfizer, Inc. provides educational information and resources related to ATTR-CM to patients and physicians. Such campaigns are expected to boost the early diagnosis of the disease and increase the treatment rate over time.

The movement undertaken by key players to provide free-of-cost medicine under their CSR activities is also projected to fuel market growth. For instance, the Pfizer Patient Assistance Program provides Pfizer medicines such as VYNDAMAX free of cost to eligible patients. People diagnosed with amyloidosis can take advantage of such programs by enrolling at the Vandalink platform. Such programs are expected to encourage physicians to prescribe this drug to a patient as drug therapy in transthyretin amyloidosis patients.

Transthyretin Amyloidosis Treatment Market Report Highlights:

  • By type, the ATTR-CM accounted for a leading share in 2024 owing to the high prevalence of the disease and the rising geriatric population. The ATTR-PN is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the presence of a strong pipeline
  • By therapy, the targeted therapy segment grabbed a dominant share in 2024 owing to the worldwide approval of the therapies and the growing prescription rate for the treatment of ATTR-CM
  • By disease type, the hereditary transthyretin amyloidosis segment dominated the market in 2024 owing to growing strategic alliances among various pharmaceutical companies aiming toward drug development along with growing pipeline drugs
  • By distribution channel, the hospital pharmacies captured the largest share in 2024 as most of the hospitals are working toward the diagnosis, research, and treatment of transthyretin amyloidosis
  • North America region held the largest share in 2024 owing to the increasing novel drug prescription, proper reimbursement policies, and higher treatment rates in the region
  • The MEA region is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the increasing incidence of ATTR amyloidosis

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Disease
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Transthyretin Amyloidosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Transthyretin Amyloidosis Treatment Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
    • 4.4.2. Vyndaqel/ Vyndamax
      • 4.4.2.1. Vyndaqel/ Vyndamax Market, 2018 - 2030 (USD Million)
    • 4.4.3. Onpattro
      • 4.4.3.1. Onpattro Market, 2018 - 2030 (USD Million)
    • 4.4.4. Amvuttra
      • 4.4.4.1. Amvuttra Market, 2018 - 2030 (USD Million)
    • 4.4.5. Tegsedi
      • 4.4.5.1. Tegsedi Market, 2018 - 2030 (USD Million)
    • 4.4.6. Wainua
      • 4.4.6.1. Wainua Market, 2018 - 2030 (USD Million)
  • 4.5. Supportive Therapy
    • 4.5.1. Supportive Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Pipeline Therapy
    • 4.6.1. Pipeline Therapy Market, 2018 - 2030 (USD Million)

Chapter 5. Transthyretin Amyloidosis Treatment Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. ATTR with Polyneuropathy (ATTR-PN)
    • 5.4.1. ATTR with Polyneuropathy (ATTR-PN) Market, 2018 - 2030 (USD Million)
  • 5.5. ATTR with Cardiomyopathy (ATTR-CM)
    • 5.5.1. ATTR with Cardiomyopathy (ATTR-CM) Market, 2018 - 2030 (USD Million)

Chapter 6. Transthyretin Amyloidosis Treatment Market: Disease Business Analysis

  • 6.1. Disease Market Share, 2024 & 2030
  • 6.2. Disease Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 6.4. Hereditary Transthyretin Amyloidosis
    • 6.4.1. Hereditary Transthyretin Amyloidosis Market, 2018 - 2030 (USD Million)
    • 6.4.2. Polyneuropathy
      • 6.4.2.1. Polyneuropathy Market, 2018 - 2030 (USD Million)
    • 6.4.3. Cardiomyopathy
      • 6.4.3.1. Cardiomyopathy Market, 2018 - 2030 (USD Million)
    • 6.4.4. Mixed Type
      • 6.4.4.1. Mixed Type Market, 2018 - 2030 (USD Million)
  • 6.5. Wild Type Amyloidosis
    • 6.5.1. Wild Type Amyloidosis Market, 2018 - 2030 (USD Million)

Chapter 7. Transthyretin Amyloidosis Treatment Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Pharmacies
    • 7.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Retail Pharmacies
    • 7.6.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.7. Online Pharmacies
    • 7.7.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Transthyretin Amyloidosis Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Alnylam Pharmaceuticals, Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Ionis Pharmaceuticals
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. AstraZeneca
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Akcea Therapeutics
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. BridgeBio Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Intellia Therapeutics, Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. SOM BIOTECH
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Oncopeptides AB
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Takeda Pharmaceutical Company Limited
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global transthyretin amyloidosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 5 Global transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 6 Global transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 7 Global transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 10 North America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 11 North America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 12 North America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 U.S. transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 15 U.S. transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 16 U.S. transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 18 Canada transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 19 Canada transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Canada transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 Mexico transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 23 Mexico transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 24 Mexico transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 27 Europe transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 28 Europe transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 29 Europe transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 31 UK transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 32 UK transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 33 UK transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 35 Germany transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 36 Germany transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 37 Germany transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 39 France transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 40 France transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 41 France transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 43 Italy transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 44 Italy transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Italy transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 47 Spain transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 48 Spain transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 49 Spain transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Denmark transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 51 Denmark transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 52 Denmark transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 53 Denmark transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Sweden transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 55 Sweden transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 56 Sweden transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 57 Sweden transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Norway transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 59 Norway transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 60 Norway transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 61 Norway transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 China transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 68 China transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 69 China transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 70 China transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Japan transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 72 Japan transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 73 Japan transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 74 Japan transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 76 India transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 77 India transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 78 India transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 80 Australia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 81 Australia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 82 Australia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 84 South Korea transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 85 South Korea transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 86 South Korea transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 88 Thailand transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 89 Thailand transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 90 Thailand transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 93 Latin America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 94 Latin America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 95 Latin America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Brazil transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 97 Brazil transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 98 Brazil transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 99 Brazil transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 101 Argentina transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 102 Argentina transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 103 Argentina transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 South Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 110 South Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 111 South Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 112 South Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117 UAE transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 118 UAE transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 119 UAE transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 120 UAE transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121 Kuwait transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 122 Kuwait transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 123 Kuwait transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 124 Kuwait transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Transthyretin amyloidosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapy and type outlook (USD Million)
  • Fig. 10 Disease and distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Transthyretin amyloidosis treatment market dynamics
  • Fig. 13 Transthyretin amyloidosis treatment market: Porter's five forces analysis
  • Fig. 14 Transthyretin amyloidosis treatment market: PESTLE analysis
  • Fig. 15 Transthyretin amyloidosis treatment market: Therapy segment dashboard
  • Fig. 16 Transthyretin amyloidosis treatment market: Therapy market share analysis, 2024 & 2030
  • Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Vyndaqel/ Vyndamax market, 2018 - 2030 (USD Million)
  • Fig. 19 Onpattro market, 2018 - 2030 (USD Million)
  • Fig. 20 Amvuttra market, 2018 - 2030 (USD Million)
  • Fig. 21 Tegsedi market, 2018 - 2030 (USD Million)
  • Fig. 22 Wainua market, 2018 - 2030 (USD Million)
  • Fig. 23 Supportive therapy market, 2018 - 2030 (USD Million)
  • Fig. 24 Pipeline Therapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Transthyretin amyloidosis treatment market: Type segment dashboard
  • Fig. 26 Transthyretin amyloidosis treatment market: Type market share analysis, 2024 & 2030
  • Fig. 27 ATTR with Polyneuropathy (ATTR-PN) market, 2018 - 2030 (USD Million)
  • Fig. 28 ATTR with Cardiomyopathy (ATTR-CM) market, 2018 - 2030 (USD Million)
  • Fig. 29 Transthyretin amyloidosis treatment market: Disease segment dashboard
  • Fig. 30 Transthyretin amyloidosis treatment market: Disease market share analysis, 2024 & 2030
  • Fig. 31 Hereditary transthyretin amyloidosis market, 2018 - 2030 (USD Million)
  • Fig. 32 Polyneuropathy market, 2018 - 2030 (USD Million)
  • Fig. 33 Cardiomyopathy market, 2018 - 2030 (USD Million)
  • Fig. 34 Mixed type market, 2018 - 2030 (USD Million)
  • Fig. 35 Wild type amyloidosis market, 2018 - 2030 (USD Million)
  • Fig. 36 Transthyretin amyloidosis treatment market: Distribution channel segment dashboard
  • Fig. 37 Transthyretin amyloidosis treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 39 Specialty pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 40 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 41 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 42 Transthyretin amyloidosis treatment market revenue, by region
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 Regional marketplace: Key takeaways
  • Fig. 45 North America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. country dynamics
  • Fig. 47 U.S. transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Canada country dynamics
  • Fig. 49 Canada transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico country dynamics
  • Fig. 51 Mexico transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Europe transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 UK country dynamics
  • Fig. 54 UK transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Germany country dynamics
  • Fig. 56 Germany transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 France country dynamics
  • Fig. 58 France transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Italy country dynamics
  • Fig. 60 Italy transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Spain country dynamics
  • Fig. 62 Spain transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Norway country dynamics
  • Fig. 64 Norway transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Sweden country dynamics
  • Fig. 66 Sweden transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Denmark country dynamics
  • Fig. 68 Denmark transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 Asia Pacific transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Japan country dynamics
  • Fig. 71 Japan transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 China country dynamics
  • Fig. 73 China transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 India country dynamics
  • Fig. 75 India transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Australia country dynamics
  • Fig. 77 Australia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 South Korea country dynamics
  • Fig. 79 South Korea transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 Thailand country dynamics
  • Fig. 81 Thailand transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Latin America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 Brazil country dynamics
  • Fig. 84 Brazil transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina country dynamics
  • Fig. 86 Argentina transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 87 MEA transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 88 South Africa country dynamics
  • Fig. 89 South Africa transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia country dynamics
  • Fig. 91 Saudi Arabia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 92 UAE country dynamics
  • Fig. 93 UAE transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 94 Kuwait country dynamics
  • Fig. 95 Kuwait transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 96 Company categorization
  • Fig. 97 Company market position analysis
  • Fig. 98 Strategic framework